Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection
Abstract Background The prevalence of viral infectious diseases has become a serious threat to public safety, economic and social development. Vaccines have been served as the most effective platform to prevent virus transmission via the activation of host immune responses, while the low immunogenic...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-12-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-022-01730-0 |
| _version_ | 1797985410921529344 |
|---|---|
| author | Jian Huo Angke Zhang Shuqi Wang Hanghang Cheng Daopeng Fan Ran Huang Yanan Wang Bo Wan Gaiping Zhang Hua He |
| author_facet | Jian Huo Angke Zhang Shuqi Wang Hanghang Cheng Daopeng Fan Ran Huang Yanan Wang Bo Wan Gaiping Zhang Hua He |
| author_sort | Jian Huo |
| collection | DOAJ |
| description | Abstract Background The prevalence of viral infectious diseases has become a serious threat to public safety, economic and social development. Vaccines have been served as the most effective platform to prevent virus transmission via the activation of host immune responses, while the low immunogenicity or safety, the high cost of production, storage, transport limit their effective clinical application. Therefore, there is a need to develop a promising strategy to improve the immunogenicity and safety of vaccines. Methods We developed a splenic-targeting biomimetic nanovaccine (NV) that can boost protective humoral and cellular immunity against african swine fever virus (ASFV) infection. The universal PLGA nanoparticles (CMR-PLGA/p54 NPs) coated with mannose and CpG (TLR9 agonist) co-modified red blood cell (RBC) membrane were prepared, which comprised a viral antigen (p54) and can be served as a versatile nanovaccine for elevating protective immunity. Results CMR-PLGA/p54 NVs could be effectively uptaken by BMDC and promoted BMDC maturation in vitro. After subcutaneous immunization, antigen could be effectively delivered to the splenic dendritic cells (DCs) due to the splenic homing ability of RBC and DC targeting capacity of mannose, which promoted antigen presentation and DCs maturation, and further elicited higher levels of cytokines secretion and specific IgG titers, CD4+ and CD8+ T cells activation and B maturation. Moreover, NVs demonstrated notable safety during the immunization period. Conclusions This study demonstrates the high potential of CMR-PLGA NPs as vaccine delivery carriers to promote humoral and cellular immune responses, and it provides a promising strategy to develop safe and effective vaccines against viral infectious diseases. |
| first_indexed | 2024-04-11T07:17:36Z |
| format | Article |
| id | doaj.art-4599c43c08ee4cdfa61cb56d8f87a69d |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-11T07:17:36Z |
| publishDate | 2022-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-4599c43c08ee4cdfa61cb56d8f87a69d2022-12-22T04:37:52ZengBMCJournal of Nanobiotechnology1477-31552022-12-0120111310.1186/s12951-022-01730-0Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infectionJian Huo0Angke Zhang1Shuqi Wang2Hanghang Cheng3Daopeng Fan4Ran Huang5Yanan Wang6Bo Wan7Gaiping Zhang8Hua He9College of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityCollege of Veterinary Medicine, International Joint Research Center of National Animal Immunology, Henan Engineering Laboratory of Animal Biological Products, Longhu Laboratory, Henan Agricultural UniversityAbstract Background The prevalence of viral infectious diseases has become a serious threat to public safety, economic and social development. Vaccines have been served as the most effective platform to prevent virus transmission via the activation of host immune responses, while the low immunogenicity or safety, the high cost of production, storage, transport limit their effective clinical application. Therefore, there is a need to develop a promising strategy to improve the immunogenicity and safety of vaccines. Methods We developed a splenic-targeting biomimetic nanovaccine (NV) that can boost protective humoral and cellular immunity against african swine fever virus (ASFV) infection. The universal PLGA nanoparticles (CMR-PLGA/p54 NPs) coated with mannose and CpG (TLR9 agonist) co-modified red blood cell (RBC) membrane were prepared, which comprised a viral antigen (p54) and can be served as a versatile nanovaccine for elevating protective immunity. Results CMR-PLGA/p54 NVs could be effectively uptaken by BMDC and promoted BMDC maturation in vitro. After subcutaneous immunization, antigen could be effectively delivered to the splenic dendritic cells (DCs) due to the splenic homing ability of RBC and DC targeting capacity of mannose, which promoted antigen presentation and DCs maturation, and further elicited higher levels of cytokines secretion and specific IgG titers, CD4+ and CD8+ T cells activation and B maturation. Moreover, NVs demonstrated notable safety during the immunization period. Conclusions This study demonstrates the high potential of CMR-PLGA NPs as vaccine delivery carriers to promote humoral and cellular immune responses, and it provides a promising strategy to develop safe and effective vaccines against viral infectious diseases.https://doi.org/10.1186/s12951-022-01730-0Red blood cell membraneTargetingBiomimetic nanovaccineCpGASFV |
| spellingShingle | Jian Huo Angke Zhang Shuqi Wang Hanghang Cheng Daopeng Fan Ran Huang Yanan Wang Bo Wan Gaiping Zhang Hua He Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection Journal of Nanobiotechnology Red blood cell membrane Targeting Biomimetic nanovaccine CpG ASFV |
| title | Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection |
| title_full | Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection |
| title_fullStr | Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection |
| title_full_unstemmed | Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection |
| title_short | Splenic-targeting biomimetic nanovaccine for elevating protective immunity against virus infection |
| title_sort | splenic targeting biomimetic nanovaccine for elevating protective immunity against virus infection |
| topic | Red blood cell membrane Targeting Biomimetic nanovaccine CpG ASFV |
| url | https://doi.org/10.1186/s12951-022-01730-0 |
| work_keys_str_mv | AT jianhuo splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT angkezhang splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT shuqiwang splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT hanghangcheng splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT daopengfan splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT ranhuang splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT yananwang splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT bowan splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT gaipingzhang splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection AT huahe splenictargetingbiomimeticnanovaccineforelevatingprotectiveimmunityagainstvirusinfection |